SIRT3 as a new potential predictive biomarker for response to CDK4/6 inhibition in ER+/HER2-metastatic breast cancer patients

被引：0
|
作者：
Manai, Maroua
Sahraoui, Ghada
Doghri, Raoudha
Gerratana, Lorenzo
D'Amico, Paolo
Zhang, Youbin
Donahue, Jeannine
Shah, Ami
Reduzzi, Carolina
Qiang, Wenan
Cristofanilli, Massimo
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-14-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-14-12
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
    Chica-Parrado, M. Rosario
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Mahoney, Timothy
    Mauer, Elizabeth
    Hanker, Ariella
    Arteaga, Carlos
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [2] CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER
    不详
    [J]. CANCER DISCOVERY, 2015, 5 (02) : 107 - 107
  • [3] Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2-breast cancer
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    [J]. ONCOTARGET, 2016, 7 (43) : 69111 - 69123
  • [4] Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a posttreatment multiomic signature for patients with ER+/HER2-metastatic breast cancer (SIDEOUT-3)
    Abu-Khalaf, Mm
    Pierobon, M.
    Denduluri, N.
    Valdes-Albini, F.
    Forero-Torres, A.
    Clark, A.
    Yung, R.
    Mita, M.
    Christensen, S.
    Awerkamp, K.
    Dunetz, B.
    Murphy, R.
    Hatzis, C.
    Zelterman, D.
    Liotta, L.
    Petricoin, E.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [5] Predicting sensitivity to CDK4/6 inhibition in ER+/HER2-breast cancer cell lines
    Bathurst, Lauren
    Liao, Linda
    Crozier, Cheryl
    Bayani, Jane
    Bartlett, John
    Spears, Melanie
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [6] Targeted therapies for ER+/HER2-metastatic breast cancer
    Yamamoto-Ibusuki, Mutsuko
    Arnedos, Monica
    Andre, Fabrice
    [J]. BMC MEDICINE, 2015, 13
  • [7] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah M.
    Liu, Qiao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2-metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors
    Kamaraju, Sailaja
    Fowler, Amy
    Cheng, Chung Yee
    Chaudhary, Lubna N.
    Burfeind, John
    Retseck, Janet
    Tevaarwerk, Amye J.
    Burkard, Mark
    Paplomata, Elisavet
    Parkes, Amanda M.
    Jorns, Julie M.
    Tarima, Sergey
    Yee, Douglas
    Rui, Hallgeir
    Lange, Carol
    Sahmoud, Tarek
    Wisinski, Kari B.
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [9] Vaginal and sexual health in patients with ER+/HER2-metastatic breast cancer (mBC)
    Shanahan, Kelly
    Sammons, Sarah
    Meisel, Jane L.
    Pluard, Timothy J.
    Kozlowski, Monica
    Carroll, Dominic
    Attias, Elizabeth
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (12): : 1296 - 1296
  • [10] Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer-A Review of the Literature
    Stanciu, Ioana-Miruna
    Parosanu, Andreea Ioana
    Orlov-Slavu, Cristina
    Iaciu, Ion Cristian
    Popa, Ana Maria
    Olaru, Cristina Mihaela
    Pirlog, Cristina Florina
    Vrabie, Radu Constantin
    Nitipir, Cornelia
    [J]. DIAGNOSTICS, 2023, 13 (05)
12345